Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil
Open Access
- 1 September 2017
- journal article
- research article
- Published by Elsevier BV in Annals of Hepatology
- Vol. 16 (5), 727-733
- https://doi.org/10.5604/01.3001.0010.2717
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized studyHepatology, 2016
- Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)Hepatology, 2016
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)Hepatology, 2016
- Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrenceHepatology, 2016
- Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1The New England Journal of Medicine, 2015
- All‐oral 12‐week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY‐3 phase III studyHepatology, 2015
- Global epidemiology and genotype distribution of the hepatitis C virus infectionJournal of Hepatology, 2014
- Association Between Sustained Virological Response and All-Cause Mortality Among Patients With Chronic Hepatitis C and Advanced Hepatic FibrosisJama-Journal Of The American Medical Association, 2012
- Relationship of Liver Disease Stage and Antiviral Therapy With Liver-Related Events and Death in Adults Coinfected With HIV/HCVJama-Journal Of The American Medical Association, 2012
- A Sustained Virologic Response Reduces Risk of All-Cause Mortality in Patients With Hepatitis CClinical Gastroenterology and Hepatology, 2011